Overview

Treatment With Metformin in Chinese Children With Alport Syndrome

Status:
Not yet recruiting
Trial end date:
2025-04-20
Target enrollment:
Participant gender:
Summary
This single-center, prospective, double-blind randomized placebo-controlled trial will evaluate the efficacy and safety of metformin in Chinese children with Alport syndrome who have received (and continue to receive)) ACEi/ARB.
Phase:
Phase 4
Details
Lead Sponsor:
Peking University First Hospital
Treatments:
Metformin